Saudi Vision 2030 & UAE Operation 300bn: Medical Device Localization & Market Entry Strategy

Two National Programs Reshaping Gulf Healthcare

Saudi Arabia and the United Arab Emirates are executing the most ambitious healthcare industrialization programs in the MENA region. Saudi Vision 2030, through its Health Sector Transformation Program (HSTP) and the National Industrial Development and Logistics Program (NIDLP), aims to fundamentally restructure the Kingdom's healthcare delivery model and localize medical product manufacturing. The UAE, through Operation 300bn and the Make it in the Emirates initiative, has designated medical devices and equipment as a priority industrial sector with a target of raising industrial GDP from AED 133 billion to AED 300 billion by 2031.

For medical device manufacturers, these programs are not abstract policy statements. They translate directly into procurement preferences, regulatory incentives, mandatory local content requirements, and investment frameworks that determine market access. This guide examines both national programs in detail and outlines practical market entry strategies for medical device companies.

Saudi Arabia: Vision 2030 Healthcare Transformation

Health Sector Transformation Program (HSTP)

The HSTP is the primary vehicle for restructuring Saudi Arabia's healthcare system. Its strategic objectives center on four pillars:

1. Facilitating access to healthcare services — through optimal coverage, comprehensive geographical distribution, and expanding e-health services
2. Improving quality and efficiency — through value-based care models, outcome evaluation, and private sector integration
3. Promoting prevention of health risks — through public health programs targeting non-communicable diseases
4. Strengthening financial sustainability — through insurance-based models and public-private partnerships (PPPs)

Privatization: The Structural Shift

The most consequential change for medical device manufacturers is the healthcare privatization program. Key targets include:

The Privatization Programme 2025 approved 9 healthcare privatization initiatives with 23 additional initiatives under review. Specific targets include:

• Establishing dialysis centres through partnerships with leading companies
• Preparing King Faisal Specialist Hospital & Research Centre for privatization to achieve regional leadership in tertiary care
• Expanding and modernizing laboratory and radiology services through private-sector partnerships
• Establishing additional medical cities through PPP schemes

For device manufacturers, privatization means a shift from single-buyer (MOH) procurement to a diversified purchaser landscape including private hospital groups, insurance-driven formularies, and PPP structures.

National Industrial Development and Logistics Program (NIDLP)

The NIDLP targets four sectors — energy, mining, industry, and logistics — with healthcare-related manufacturing as a key industrial pillar. Specific medical device and pharma targets:

• Localize 40% of pharmaceutical industry market value (currently only ~20% of local demand met through domestic production)
• Raise local content in oil and gas to 75%
• Maximize industrial GDP contribution to SAR 176 billion
• Create 219,000+ new jobs
• Achieve 50% localization in military expenditure
• Localize 70% of the supply chain for basic and intermediate chemicals

LCGPA: Local Content Requirements

The Local Content and Government Procurement Authority (LCGPA) is the enforcement mechanism. Its requirements directly affect medical device manufacturers selling to government entities:

The LCGPA's Economic Participation Policy requires foreign companies to submit localization commitments as part of government procurement bids. These commitments can include establishing local manufacturing facilities, technology transfer agreements, or joint ventures with Saudi partners.

SFDA Manufacturing Guidance (MDS-G11 Version 2.0)

Effective July 7, 2025, the SFDA released Version 2.0 of the "Guidance on Manufacturing Paths of Medical Devices" (MDS-G11), which defines three manufacturing pathways:

1. Full local manufacturing — Complete production in Saudi Arabia with full SFDA facility licensing
2. Partial local manufacturing (assembly) — Final assembly, packaging, or labeling in Saudi Arabia with components sourced internationally
3. Third pathway — A hybrid model for technology transfer and progressive localization

This guidance is "a cornerstone of SFDA's strategy to promote localization, streamline compliance, and support innovation within Saudi Arabia's rapidly evolving medical device industry — all aligned with Vision 2030 and the National Strategy for Industry."

Saudi Health Budget & Investment Flows

Saudi Arabia allocated SAR 260 billion ($69.3 billion) to health and social development in its 2025 budget, representing the second-largest share of government spending. The 2026 budget maintains this commitment while prioritizing spending efficiency.

At the Global Health Exhibition 2025 in Riyadh, $35.5 billion in deals were signed, including:

• $8.4 billion for hospital and healthcare infrastructure projects
• SAR 2.4+ billion through PIF-backed Lifera partnerships with global pharmaceutical companies (Sanofi, MSD, Pfizer, BD, Roche, Siemens Healthineers) for localized manufacturing and R&D
• $1.5 billion from Hillhouse for pharmaceutical manufacturing and R&D
• $675 million from Al Fozan Holding for next-generation clinical infrastructure
• $266 million from BD for medical technology localization and clinical training
• SAR 235 million+ from Modon Properties for new pharmaceutical manufacturing plants

United Arab Emirates: Operation 300bn & Industrial Strategy

Operation 300bn Overview

Operation 300bn, managed by the Ministry of Industry and Advanced Technology (MoIAT), aims to increase the industrial sector's contribution to UAE GDP from AED 133 billion ($36.2 billion) to AED 300 billion ($81.6 billion) by 2031. The strategy operates across 16 initiatives and identifies 11 vital industrial sectors, with "Medicine, medical equipment and supplies" designated as a priority sector.

The program's key enablers include:

• Flexible financing through the Emirates Development Bank (EDB)
• Advanced technology roadmap supporting Industry 4.0 adoption
• Industrial data management and digital transformation
• Quality infrastructure (standards, metrology, conformity assessment)
• Attractive energy pricing for industrial operations
• Industrial Law providing regulatory clarity for manufacturers

Healthcare Free Zones: The Gateway

The UAE offers dedicated healthcare free zones that provide uniquely favorable conditions for medical device companies:

Dubai Healthcare City (DHCC)

DHCC hosts international institutions including Moorfields Eye Hospital, serving patients from across the Gulf, Africa, and South Asia. The Phase 3 expansion positions Dubai to attract 2 million medical tourists annually by 2030, contributing AED 25 billion to the economy.

Dubai Science Park (DSP)

DSP complements DHCC by focusing on research, innovation, and commercial applications in life sciences. Together, they form "the backbone of Dubai's strategy: combining medical services, research infrastructure, and commercial incentives to attract global players while nurturing local capability."

EDE Regulatory Framework

The Emirates Drug Establishment (EDE), established by Federal Decree-Law No. 38 of 2024 (effective January 2, 2025), consolidated 44 core regulatory services previously under MOHAP. For medical device manufacturers, the EDE now manages:

• Product registration and marketing authorization
• Establishment licensing for manufacturers, warehouses, and marketing offices
• Import permits for registered and unregistered devices
• Variations, renewals, and post-market surveillance
• Clinical study accreditation

In February 2026, the EDE introduced a landmark anti-monopoly mechanism requiring companies to appoint more than one agent for each medical product distributed in the UAE, breaking the previous single-distributor model.

100% Foreign Ownership

Since the 2021 amendment to UAE commercial law, 100% foreign ownership is permitted for most business activities — including healthcare — in both free zones and the mainland. This removed a longstanding barrier for international medical device companies and catalyzed a new wave of foreign-backed healthcare enterprise.

Market Entry Strategy: Choosing Your Path

Option 1: Direct Registration with Local Authorized Representative

Best for: Established manufacturers with existing product portfolios, limited initial investment appetite.

This approach provides market access but does not satisfy local content requirements for government tenders in Saudi Arabia.

Option 2: Local Assembly / Partial Manufacturing

Best for: Companies seeking government procurement eligibility while managing investment risk.

Saudi Arabia's SFDA MDS-G11 Version 2.0 explicitly supports this path through "partial local manufacturing (assembly)" — final assembly, packaging, or labeling in-country with internationally sourced components.

Requirements include:

• SFDA-licensed manufacturing facility
• ISO 13485 certification for the local site
• Qualified person responsible for regulatory compliance
• Local content calculation demonstrating minimum threshold (currently 40% for "Made in Saudi" designation)

Option 3: Full Local Manufacturing

Best for: Large-volume products, companies with long-term MENA strategies, products targeting government procurement.

Both countries offer incentives:

Saudi Arabia:

• NIDLP incentives including subsidized industrial land, preferential energy pricing, and financing through Saudi Industrial Development Fund (SIDF)
• LCGPA mandatory list inclusion for Saudi-made products
• Preferential scoring in NUPCO framework agreements
• SFDA regulatory pathway for locally manufactured products

UAE:

• Operation 300bn priority sector designation
• MoIAT "Make it in the Emirates" incentives
• Free zone benefits: 100% ownership, 0% tax, 0% customs
• EDB financing support
• DHCC/DSP ecosystem access

Option 4: Joint Venture / Technology Transfer

Best for: Companies willing to share technology in exchange for market access and local content compliance.

Saudi Arabia's Economic Participation Policy explicitly encourages technology transfer as a localization commitment. Major global companies have already taken this path:

• BD committed $266 million to localize medical technologies and deliver clinical training
• PIF's Lifera entered partnerships with Sanofi, MSD, Pfizer, and Jamjoom Pharma for vaccine and biopharmaceutical development
• Siemens Healthineers established localization partnerships for advanced manufacturing and R&D

Practical Recommendations

For Saudi Arabia Market Entry

1. Register with SFDA immediately — MDMA authorization is a prerequisite for all market activities.
2. Appoint an Authorized Representative — Required for all foreign manufacturers; the AR serves as your regulatory liaison.
3. Calculate your local content score — Even without local manufacturing, understand how your products score under LCGPA methodology.
4. Identify Saudi manufacturing partners — Evaluate technology transfer or joint venture opportunities, especially for high-volume products.
5. Monitor LCGPA Mandatory List updates — Products added to the mandatory list require local sourcing for government procurement.
6. Prepare NUPCO-ready documentation — Include pharmacoeconomic dossier, local content calculations, and pricing benchmarks in SAR.

For UAE Market Entry

1. Register with EDE — Use the EDE portal at www.ede.gov.ae for all device registration activities.
2. Appoint a Local Authorized Representative (LAR) — Mandatory for all foreign manufacturers.
3. Choose your business structure — Free zone (DHCC, DSP) for 100% ownership and tax benefits; mainland for direct government contracting.
4. Consider DHCC Phase 3 incentives — 40% rent discount for first 3 years, fast-track licensing, Golden Visa eligibility.
5. Plan for multiple distributors — EDE's February 2026 anti-monopoly policy requires more than one agent per product.
6. Leverage Operation 300bn — If manufacturing locally, access MoIAT incentives, EDB financing, and priority sector benefits.

Looking Ahead: 2026–2030

The structural trajectory is clear. Both Saudi Arabia and the UAE are moving from "import everything" to "localize strategically" in medical devices. The LCGPA's February 2026 announcement of increased minimum local content requirements (effective August 2028) signals that localization thresholds will continue rising.

For medical device manufacturers, the window for establishing a local presence on favorable terms is narrowing. Companies that move in 2026–2027 will benefit from early-mover incentives, established partnerships, and regulatory familiarity. Those that delay will face higher localization barriers and a more competitive landscape dominated by companies that invested early.

The data is unambiguous: Saudi Arabia committed $35.5 billion in healthcare deals at a single event in 2025. The UAE is investing AED 8 billion in DHCC Phase 3 alone. The question for medical device companies is not whether to enter these markets, but how quickly they can build the local infrastructure necessary to compete for the procurement opportunities these investments will generate.